Holen Sie sich die Stockscreener-App
7.84
25.90%
1.58
Handel nachbörslich:
7.82
-0.02
-0.26%
Schlusskurs vom Vortag:
$6.26
Offen:
$6.26
24-Stunden-Volumen:
652.01K
Relative Volume:
0.46
Marktkapitalisierung:
$49.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.46M
KGV:
-0.56
EPS:
-14
Netto-Cashflow:
$-24.56M
1W Leistung:
+37.79%
1M Leistung:
+167.63%
6M Leistung:
+455.04%
1J Leistung:
-41.40%
1-Tages-Spanne:
$6.1425
$7.9039
1-Wochen-Bereich:
$5.81
$7.9039
52-Wochen-Spanne:
$1.20
$15.50
Evaxion A S Adr Stock (EVAX) Company Profile
Vergleichen Sie EVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
7.84 | 39.54M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion A S Adr Aktie (EVAX) Neueste Nachrichten
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting - GlobeNewswire Inc.
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright - TipRanks
Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck - TipRanks
Evaxion A/S (NASDAQ:EVAX) Trading Down 0.7% – Should You Sell? - Defense World
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Evaxion Biotech Reports Q2 2025 Financial Results - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
European Equities See Growth In US Trade - Finimize
Analysts’ Top Healthcare Picks: Encompass Health (EHC), Evaxion Biotech (EVAX) - The Globe and Mail
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion secures Nasdaq listing with equity boost - Investing.com
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Finanzdaten der Evaxion A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):